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Abstract A 29-year-old man presented to his primary care
physician with nausea, severe weight loss and muscle
weakness. He had a hard, fixed neck swelling. He was
severely hypercalcaemic with 10-fold increased parathyroid
hormone (PTH) concentrations. A diagnosis of primary
hyperparathyroidism was established and the patient was
referred for parathyroidectomy. At neck exploration, an
enlarged parathyroid gland with invasive growth into the
thyroid gland was found and removed, lymph nodes were
cleared and hemithyroidectomy was performed. A sus-
pected diagnosis of parathyroid carcinoma was confirmed
histologically. Serum calcium and PTH levels normalised
post-operatively, but hyperparathyroidism recurred within
3 years of surgery. Over the following 17 years, control of
hypercalcaemia represented the most difficult challenge
despite variable success achieved with repeated surgical
interventions, embolisations, radiofrequency ablation of
metastases and treatment with calcimimetics, bisphosphonates
and haemodialysis using low-dialysate calcium. In this paper,
we report the challenges and pitfalls we encountered in the
management of our patient over nearly two decades of follow-
up and review recent literature on the topic.
Keywords Parathyroids.Parathyroidectomy.
Radiofrequency ablation.Embolisation.Cinacalcet.
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Introduction
Parathyroid carcinoma is a rare disorder, accounting for
0.1% to 5.0% of all cases of primary hyperparathyroidism
[1–5]. The disease presents at a mean age of 50 years and is
equally likely to occur in males as in females [2–6]
(Table 1). Clinical and biochemical manifestations are
those of severe primary hyperparathyroidism often with
renal and skeletal complications [2–5, 7]. A palpable neck
mass can be felt in 30–76% of patients [3, 5, 8, 9].
Parathyroid carcinoma is associated with germline and
somatic mutations in the HRPT2 gene [3, 10] and with
irradiation of the neck for other pathologies [3, 11].
A diagnosis of parathyroid carcinoma is suggested by
the presence of intra-operative features of local invasion
and the diagnosis is confirmed by the World Health
Organization histopathological criteria for parathyroid
carcinoma. These include the presence of vascular invasion,
perineural space invasion, capsular penetration with growth
into adjacent tissues and/or metastasis [12].
Although parathyroid carcinoma is a slow-growing
tumour, it inevitably metastasises and is invariably fatal
due to the eventual inability to control hypercalcaemia.
Survival is estimated to range from 50% to 86% at 5 years
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HORM CANC (2010) 1:205–214 207and 35–70% at 10 years [1–6, 13, 14]. The most effective
treatment for parathyroid carcinoma is radical surgery with
en bloc removal of the lesion together with the ipsilateral
thyroid, thyroid isthmus and lymph nodes [2, 3, 5, 13, 15].
Surgery is also the treatment of choice in case of local
recurrence or development of metastases [5, 7, 16],
although radiotherapy [2–5, 8, 9], chemotherapy [3, 5, 9,
17, 18], embolisation [19] or radio frequency (RF) ablation
[19–21] may also be attempted.
We report here the nearly two decades’ odyssey of a male
patient with multiple metastases from parathyroid carcinoma,
describing in the process the challenges and pitfalls we
encountered in the management of this difficult malignancy.
We also review all original case reports and case series on
parathyroid carcinoma, fulfilling the WHO criteria and with a
follow-up of at least 6 months after initial parathyroidectomy,
which were published in the English literature since the last
large review on this topic in 2001 [3]. The literature search
was conducted in PubMed using the keywords (“Parathyroid
Neoplasms” OR “Parathyroid carcinoma” OR “Parathyroid
cancer” OR “Parathyroid cancers”)A N D( “Case Reports”
OR “case report” OR “case” OR “cases”). The last search
was conducted on June 2, 2010. Patients with changes
suggestive of carcinoma in the context of autonomous
(tertiary) hyperparathyroidism were excluded because of the
controversy in diagnosing malignancy in this case. Of an
initial 872 publications, only 45 fulfilled the WHO criteria
for parathyroid carcinoma and follow-up as per our search
criteria, and were selected for further analysis.
Case Report
A 29-year-old man presented to his primary care physician
with a 2-month history of severe weight loss (20 kg)
associated with polyuria, polydipsia, nausea, muscle weak-
ness, difficulty in concentrating and debilitating tiredness.
On physical examination, he was clinically dehydrated and
had a palpable hard, fixed swelling in the left side of the
neck. He was using no medication and had no significant
past or family history. Laboratory investigations revealed a
severe hypercalcaemia of 4.9 mmol/l (normal range 2.15–
2.55 mmol/l), a decreased creatinine clearance of 45 ml/min
(normal >120 ml/min) and a 10-fold increased serum intact
parathyroid hormone (PTH) concentration: 88 pmol/l (normal
<8 pmol/l). These findings suggested a diagnosis of severe
primary hyperparathyroidism probably due to parathyroid
carcinoma. No further investigations were requested; the
patient was intensively rehydrated and referred for parathy-
roidectomy. At neck exploration, an enlarged parathyroid
gland (3.5×3×3.5 cm) invading the ipsilateral thyroid lobe
was found and removed from the left side of the neck
(Fig. 1). A left hemithyroidectomy was also performed. The
diagnosis of parathyroid carcinoma was confirmed histolog-
ically by the finding of capsular and vascular invasion.
Serum calcium and PTH concentrations normalised within a
few days of surgery associated with a significant improve-
ment in renal function. A second surgery was performed
within 1 month of the first surgery to ensure complete
removal of all malignant tissue and provide a negative
surgical margin. The patient was started on a course of
radiotherapy, which had to be discontinued before comple-
tion because of severe pharyngitis and oesophagitis.
A recurrence of hyperparathyroidism was documented on
routine laboratory control 3 years after parathyroidectomy. This
wasmild, with aserumcalciumconcentrationof2.74 mmol/l,a
PTH concentration of 8.4 pmol/l and a stable creatinine
clearance of 75 ml/min. The patient was completely asymp-
tomatic. Tc99m-MIBI-SPECTand ultrasonography identified a
lesion in the left side of the neck, which was found to be a local
recurrence of the primary tumour at extensive bilateral neck
exploration. The recurrent tumour had invaded the oesophagus,
part of which was excised and reconstructed using tissue from
the sternocleidomastoid muscle. The edges of the excised
specimen were tumour free and resected draining lymph nodes
were clear of tumour tissue. DNA analysis of the resected
recurrent tumour demonstrated a somatic HRPT2 mutation,
c.165delC located on exon 2 [22]. Despite the radical nature
of the surgery, mild hyperparathyroidism persisted post-
operatively, suggesting the presence of residual probably
Fig. 1 Disease course of our patient spanning over 17 years
208 HORM CANC (2010) 1:205–214metastatic tumour tissue. No further localisation studies or
surgery were planned principally because of the patient’s
reluctance to undergo further surgery but also because of the
mild nature of the hyperparathyroidism. Closer clinical
monitoring was arranged.
Over the following 4 years, serum calcium and PTH
concentrations and bone turnover markers slowly increased,
and periods of dehydration were associated with transient
worsening of renal function, which remained, however, on
the whole stable despite persistent hypercalciuria and
development of nephrocalcinosis. Progressive bone loss,
predominantly cortical, was also documented and treatment
with the non-nitrogen-containing bisphosphonate clodro-
nate was started, resulting in normalisation of bone turnover
and stabilisation of BMD measurements. Rehydration and
treatment with bisphosphonates eventually failed in con-
trolling hypercalcaemia and bone loss. Localisation studies
were undertaken to identify the source of PTH production.
Ultrasound (US), selective venous sampling for PTH (SVS)
and CT scan of the neck succeeded in localising a small
dense lesion in the left supraclavicular region. CT scan of
the thorax also revealed a small solitary lesion of 1-cm
radius in the inferior lobe of the right lung (Fig. 2a). The
patient refused to undergo a thoracotomy, but did agree to a
fourth neck exploration at which a lymph node metastasis
was excised from the left supraclavicular region (Fig. 1).
Although less severe, hyperparathyroidism persisted post-
operatively, as expected due to the unresected lung
metastasis. Two attempts at embolisation of the lung
metastasis failed to reduce tumour load. In contrast,
radiofrequency ablation (RFA) of the lesion, although
complicated by an episode of severe pleuritis, was very
successful in achieving biochemical remission, with serum
PTH concentrations decreasing from 265 pmol/l to
<1 pmol/l (Fig. 2), suggesting that the metastasis targeted
with RFA was the only source of PTH secretion. However,
remission was not permanent and PTH levels started to rise
within 9 months of RFA. The patient finally agreed to
undergo a right inferior lobectomy (Fig. 3), which was
complicated by multiple small cerebral infarcts resulting in
right haemianopia, dysphasia, acalculia and transient
epilepsy. Disappointedly, there was also only partial
improvement in serum calcium and PTH concentrations,
which continued to increase within 2 months of lobectomy
(Fig. 3).
Further localisation studies, in the form of Tc99m-
MIBI-SPECT and a CT scan of the neck and thorax,
were unable to localise any residual pathological
Fig. 2 Radiological (a pre-RF ablation, b after RF ablation) and biochemical changes after RF ablation of the lung metastasis, demonstrating a
severe drop in serum PTH concentrations, which persisted for almost a year
HORM CANC (2010) 1:205–214 209parathyroid tissue suggesting the presence of (micro)
metastasis. The now available calcimimetic cinacalcet
was prescribed eventually at a maximum dose of 90 mg
twice daily, which decreased PTH concentrations from
120 pmol/l to 85 pmol/l, stabilised calcium concentrations to
about2.80mmol/landstabilisedcreatinineclearanceat51ml/
min.Inthe courseofthe following year, serum calcium and
PTH concentrations further increased, however, despite
maximal doses of cinacalcet and intermittent intravenous
bisphosphonates.
Repeat Tc99m-MIBI-SPECT and CT scan of the
thorax, now demonstrated a new large (4×3×2 cm)
subcarinal mediastinal metastasis, which was successfully
excised using a transpericardial approach (Fig. 4). The
elimination of the source of PTH secretion was associated
with a very severe hungry bone syndrome for which the
patient needed intensive care for over 2 months, requiring
very large doses of iv administered calcium (up to 14 g/
day) and maximal doses of active vitamin D metabolites.
Remission lasted for more than 1 year, after which PTH
levels started to rise again and a new metastatic lesion was
localised pretracheally in the upper mediastinum on CT
scan of the thorax. There was also suggestion of a second
subcarinal lesion at the site of the previously excised
metastasis.
In view of the complications associated with his
previous surgeries, the patient was at that stage again
reluctant to undergo any further surgery. Within the next
few months, PTH steadily increased associated with
uncontrollable hypercalcaemia and deteriorating renal function
eventually requiring haemodialysis using a very-low-dialysate
calcium concentration. Localisation studies confirmed the two
previously identified pretracheal and subcarinal mediastinal
lesions. The pretracheal lesion was accessible from the neck
and was radically removed by a cervical approach (Fig. 1).
There were no post-operative complications and serum PTH
concentration decreased from 590 pmol/l to 155 pmol/l, as
expected due to the remaining subcarinal mediastinal metas-
tasis. Surgical removal of this metastasis would have required
a third thoracotomy, which would be associated with too high
an operative risk, especially in view of the patient’sp o o r
clinical condition. Excision of the metastasis by mediastino-
scopy was also not considered to be an option because of
multiple scarring due to previous surgeries. The patient remains
on haemodialysis and is still treated with cinacalcet, with
intermittent courses of intravenous bisphosphonates.The patient
was not consideredtobe acandidatefor PTH immunisation[23,
24] because of surgical clearance of cervical and mediastinal
lymph nodes, poor general immune status and recurring
infections.
Fig. 3 Radiological and biochemical changes following lobectomy of the lung metastasis, which resulted in only partial improvement in serum
calcium and PTH concentrations
210 HORM CANC (2010) 1:205–214Review of the Literature 2001–2010
Sixty-two new cases have been reported in the literature
since the last published review in 2001 [3], and data of
these cases are summarised in Table 1. The median age of
the reported patients was 50 years (21–79) and there was an
equal number of men and women reported. Data on initial
presentation were available in 43 of the 62 patients (69%),
37 of which were symptomatic (86%). Polyuria and polydipsia
were reported in nine patients (21%), constipation in seven
(16%), tiredness in 13 (30%), bone and joint pain in 17 (40%),
muscle weakness in seven (16%), nausea and vomiting in 10
(23%) and weight loss in seven patients (16%). Seventeen
patients (40%) had renal stones and six patients (14%) had
sustained a documented fracture. A palpable neck mass was
reported in 22 of 27 patients in whom this was checked (81%).
Similar to the review of 2001, surgery is still the most
frequently chosen therapy for the initial treatment of
parathyroid carcinoma but also for the treatment of
recurrent or metastatic parathyroid carcinoma (Table 1).
It is of note that the use of both chemotherapy and
radiotherapy has decreased over the last 10 years, likely
due to several reports and reviews which showed
disappointing results [2–5] .T h el a s tc a s er e p o r to nt h e
use of chemotherapy and radiotherapy dates from 2005
and 2008, respectively (Table 1). In contrast to the review
of 2001, reports on the use of the newer techniques
embolisation (n=1), radiofrequency ablation (n=3) and
PTH immunisation (n=1) have been recently published,
although the number of cases reported is still very limited.
Use of the calcimimetic, cinacalcet, has increased over the
last few years after the first report in 2007, while the use
of bisphosphonates has remained stable.
The median follow-up reported in the 62 cases is
relatively short at 3 years (range 0.5–20 years), considering
that the average time to a first recurrence is also
approximately 3 years [1, 3]. This could explain why only
27 of the 62 patients (44%) developed a local recurrence
and/or distant metastasis and nine patients (15%) died as a
result of parathyroid carcinoma during the reported follow-
up period.
Discussion
To our knowledge, we report here one of the longest
survival and follow-up in one centre of a patient with
recurrent metastatic parathyroid carcinoma. Although
parathyroid carcinoma is a slow-growing tumour, it is
associated with a relatively high incidence of local
recurrence (40–82% within 5 years) [1–3, 5, 6, 13].
Metastases tend to occur later in the course of the disease
with spread to cervical nodes (30%), lung (40%) and liver
(10%), via both lymphatic and haematogenous routes [3].
Survival is estimated to range from 35% to 70% at
10 years [1–6, 13, 14], with an average survival of 6 years
after local recurrence, and of 4.5 years after the develop-
ment of distant metastases [2].
Fig. 4 CT scan of the thorax
demonstrating a large (4×3×
2 cm) subcarinal mediastinal
lymph node metastasis (white
arrow)( a, b), which was
successfully excised using a
transpericardial approach (c)
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of survival include delay in diagnosis, the presence of
locally invasive features, distant metastasis at diagnosis
and the radical nature of initial surgery [3, 6, 13, 14]. A
further important determinant of survival and disease-free
survival is the due care taken at initial surgery to avoid
rupturing the capsule of the gland to prevent local seeding
of tumour tissue [3]. Initial surgery has been reported not
to be radical in up to 48% of patients because of failure to
establish the diagnosis of parathyroid carcinoma pre- or
intra-operatively [6, 14] .T h i sw a sa l s ot h ec a s ei no u r
patient at initial surgery, despite very suggestive clinical
features of parathyroid carcinoma, in the form of severe
hyperparathyroidism in a young male patient, palpable
neckswellingandintra-operative featuresoflocal invasion.A
secondsurgeryhadtobeperformedwithin1monthofthefirst
to ensure complete removal of all malignant tissue and to
provide a negative surgical margin.
The main determinant of survival in all patients
remains, however, the eventual inability to control
hypercalcaemia [2, 5] and its association with fatal renal
and cardiovascular complications [1, 2, 5, 7]. End-stage
renal failure has been reported in up to 84% of patients
due the deleterious effects of severe persistent hyper-
calcaemia on kidney function [2, 5, 7]. A persistently
elevated circulating PTH level is also associated with
increased bone turnover and bone loss predominantly at
cortical sites and with incre a s e dr i s ko ff r a c t u r e s .I n
parathyroid carcinoma, the main goal of treatment is
control of hyperparathyroidism by eradicating the source
of PTH secretion [7, 16].
Although the morbidity associated with re-exploration of
the neck is estimated to be 6–17% [7], that of re-exploration
of the mediastinum or lungs is clearly much higher. In our
patient, the recurrent laryngeal nerve had to be unavoidably
sacrificed during the second surgical intervention due to
invasive growth of remnants of the primary tumour, resulting
in transient loss of voice and permanent hoarseness.
Subsequent lung surgery was associated with severe
thrombo-embolic complications.
The increasing morbidity attached to repeated surgical
interventions has led to the search for other treatment
options, such as radiotherapy, chemotherapy, RF ablation,
embolisation, use of the calcimimetic cinacalcet and PTH
immunisation. Although parathyroid tumours are relatively
resistant to radiotherapy [2–5], this management approach
showed some promise as adjuvant treatment for microscopic
residualdisease[8, 9]. In our patient, the prescribed course of
radiotherapy could not be completed due to the development
of severe side effects in the form of pharyngitis and
oesophagitis.
Embolisation of localised and/or ectopic parathyroid
adenomas has been reported to have only limited success
[19, 25–27], and in metastatic parathyroid carcinoma,
embolisation has only been described in combination with
RF ablation in one patient [19]. In our patient, the outcome
of twice attempted embolisation of a lung metastasis was
disappointing, largely because it was not technically possible
to selectively embolise the arterial branch that fed the lung
metastasis.
The outcome of combined embolisation and RF ablation
in a patient with liver metastasis due to parathyroid
carcinoma [19], and the effectiveness of RF ablation in
various types of cancer [28] has led us to consider RF
ablation in our patient. This approach was indeed very
successful in eradicating PTH production by the metastasis,
as has also been subsequently reported in two patients with
parathyroid carcinoma and lung metastases [20, 21]. The
beneficial effect was unfortunately transient, lasting only
9 months after the procedure, when PTH production was
documented to resume from the same site.
In parathyroid carcinoma, attempts at reducing tumour
load are not always successful, in which case control of
serum calcium by other means becomes central to prevent
the deleterious effects of hypercalcaemia on various organ
systems. Intensive rehydration, use of medications such as
bisphosphonates and calcimimetics and use of dialysis
represent diverse means to control hypercalcaemia and are
often used in combination. Bisphosphonates decrease the
skeletal efflux of calcium from bone by suppressing
osteoclast-mediated bone resorption and overall bone
turnover [3]. These agents, however, have no effect on
renal tubular reabsorption of calcium so that they improve
hypercalcaemia but do not normalise serum calcium [3, 29].
Cinacalcet is a calcimimetic, which reduces parathyroid
hormone secretion by binding to the calcium-sensing
receptor on parathyroid cells, increasing the sensitivity of
these cells to extracellular calcium concentrations [15, 30,
31]. These agents are widely used in the management of
secondary and tertiary hyperparathyroidism in renal failure
and have been also recently registered for the management
of primary hyperparathyroidism, including that due to
parathyroid carcinoma. In our patient, combined treatment
with bisphosphonates and cinacalcet resulted in reasonable
control of the hypercalcaemia initially, but eventually failed
to do so, even when used at maximal doses. Dialysing
against low-dialysate calcium became necessary in order to
better control the hypercalcaemia.
The very high operative risks associated with a third
thoracotomy, the patient’s poor lung function and current
metabolic status despite regular dialysis, preclude the
option of further surgery to remove the identified source
of PTH secretion. PTH immunisation is being explored as a
potential non-invasive option, although experience with this
approach is still limited and the patient’s general condition
may not permit its use [23, 24, 32].
212 HORM CANC (2010) 1:205–214Although we are rapidly running out of options in the
management of our patient, we believe that we have
nonetheless managed to secure for him a longer albeit not
disease-free survival. This clinical case with a follow-up
spanning over 17 years illustrates that the long-term
management of patients with metastatic parathyroid carcinoma
remains indeed a daunting task, despite all recent imaging,
surgical and medical advances.
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